BACKGROUND: Disease surveillance in @entity1 with @entity150 is important for early diagnosis of progression and @entity3 and for optimised treatment. OBJECTIVE: To develop urine and plasma assays for disease surveillance for @entity1 with @entity2557 and @entity10160 @entity5 mutations. DESIGN, SETTING, AND @entity1 : Droplet digital polymerase chain reaction (ddPCR) assays were developed and @entity5 DNA from two @entity1 cohorts was screened for @entity2557 and @entity10160 hotspot mutations. One cohort included 363 @entity1 with non-muscle-invasive @entity150 (NMIBC). The other cohort included 468 @entity1 with @entity150 undergoing radical cystectomy (Cx). Urine supernatants (NMIBC n=216, Cx n=27) and plasma samples (NMIBC n=39, Cx n=27) from @entity1 harbouring mutations were subsequently screened using ddPCR assays. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Progression-free survival, recurrence-free survival, and overall survival were measured. @entity16043 's exact test, the Wilcoxon rank-sum test and Cox regression analysis were applied. RESULTS AND LIMITATIONS: In total, 36% of the NMIBC @entity1 (129/363) and 11% of the Cx @entity1 (44/403) harboured at least one @entity2557 or @entity10160 mutation. Screening of DNA from serial urine supernatants from the NMIBC cohort revealed that high levels of @entity5 DNA (tDNA) were associated with later disease progression in NMIBC (p=0.003). Furthermore, high levels of tDNA in plasma samples were associated with recurrence in the Cx cohort (p=0.016). A positive correlation between tDNA levels in urine and plasma was observed (correlation coefficient 0.6). The retrospective study design and low volumes of plasma available for analysis were limitations of the study. CONCLUSIONS: Increased levels of @entity2557 and @entity10160 mutated DNA in urine and plasma are indicative of later progression and @entity3 in @entity150 . @entity1 SUMMARY: Urine and plasma from @entity1 with @entity150 may be monitored for diagnosis of progression and @entity3 using mutation assays.

Liquid Biopsy Analysis of @entity2557 and @entity10160 Hotspot Mutations for Disease Surveillance in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS', 'PATIENT'] @entity2557 :: ('2261', 'Gene') :: ['FGFR3'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity16043 :: ('76720', 'Species') :: ['Fisher'] @entity10160 :: ('5290', 'Gene') :: ['PIK3CA']
@entity150 :: (MESH:D001749,Disease) :: ['Bladder Cancer']
